Roche has acquired mobile diabetes management platform mySugr to form a leading open platform for digital diabetes management. For Roche, the acquisition will allow the company to expand its position in the diabetes management market.As part of the acquisition, mySugr will remain as a separate legal entity with an open platform for all diabetes devices and services. Users will continue to have the ability to automatically upload blood glucose data from their preferred device into the mySugr
Read More
Diabetes Management Platform | Type 1 & 2 Diabetes Patients | News, Analysis, Insights - HIT Consultant
Glooko Raises $35M to Expand Diabetes Data Platform Internationally
Glooko, a Mountain View, CA-based provider of diabetes data management has rasied $35 million in Series C funding led by Georgian Partners with participation from Insulet Corporation, Mayo Clinic, Canaan Partners, Social Capital, Medtronic and Samsung NEXT. The company plans to use the funding to expand its’ commercialization efforts in France, Germany, the U.K., Asia and the Middle East, and further development efforts in data analytics and artificial intelligence to provide personalized
Read More
Study: Glooko’s Diabetes Mobile App Improved Glucose & A1C Rates
Diabetes data management company Glooko announced that its mobile app was associated with a drop in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes, according to results of two retrospective studies. Furthermore, usage of the Glooko mobile app was also associated with an increase in blood glucose test rate. Increased blood glucose testing rates have been shown to directly correlate with improvements in glycemic control, as evidenced by this
Read More
Livongo Launches New Direct-to-Consumer Diabetes Management Program
Livongo Health, a consumer digital health company focused on empowering people with chronic conditions to live better and healthier lives, today announced partnerships with the American Diabetes Association, Beyond Type 1, Diabetes Hands Foundation, and JDRF to launch the Livongo Family Care Plan. The Family Care Plan is a comprehensive direct-to-consumer diabetes management program for people with diabetes and those who love them.The partnership also provides everyone who subscribes to the
Read More
WellDoc Founders Launch FDA-Cleared Mobile Insulin Titration App for Diabetes Management
The team that created the first FDA-cleared mobile app for diabetes management at WellDoc has launched a completely new digital health company, Amalgam Rx. The new company is focused on developing next-generation, evidence-based digital therapies that empower and engage patients with chronic diseases. Amalgam’s first product, iSage Rx is the first FDA 510(k)-cleared, prescription-only, mobile insulin titration app of all brands of basal insulin including Lantus, Levemir, Toujeo, Tresiba and
Read More
Samsung Health Integrates with WellDoc’s Consumer Diabetes Health App
Today, WellDoc announced it has entered a joint commercial partnership agreement with Samsung. The enhanced partnership with WellDoc gives Samsung an opportunity to serve global consumers who are ready to embrace the combined health innovations that both companies plan to offer. Samsung also becomes a distribution channel for WellDoc.The companies will integrate WellDoc’s newly-released consumer diabetes health app, BlueStar® C, with the recently launched Samsung Health, a mobile one-stop shop
Read More
Livongo Health Raises $52.5M to Expand Diabetes Management to International Markets
Livongo Health, a consumer digital health company that is empowering people with chronic diseases to live better has raised $52.5 million in growth funding co-led by existing investor General Catalyst and international investment company Kinnevik. Singapore-based EDBI, American Investment Holdings LLC, and Microsoft Ventures also joined the round including participation from previous investors. The company plans to utilize the funding to expand its diabetes management to international markets
Read More
Common Sensing, Welkin Health Partner to Develop Innovative Insulin Adherence Program
Insulin adherence remains a significant challenge with approximately 62 percent of patients discontinuing insulin in the first three months and 82 percent in the first year. To resolve this challenge, Common Sensing and Welkin Health have partnered to develop an innovative new program aimed at improving insulin adherence for people living with diabetes. A first-of-its-kind initiative, the program will combine insulin dosing data, wirelessly transmitted from Common Sensing’s Gocap™, real-time
Read More
Grady Health Goes Live on Glytec’s Personalized Diabetes Therapy Management Platform
Atlanta’s Grady Health System has implemented the Glytec eGlycemic Management System®, a personalized diabetes therapy management solution seamlessly integrated with the Epic EMR. Glytec's eGMS® is currently deployed across all critical care areas -- each assigned an interdisciplinary team of pharmacy, medical and nursing staff to provide localized glycemic governance.Integration with Epic EMReGMS integration with Epic's EMR will allow users direct access from a patient’s chart without the need
Read More
WellDoc Receives FDA 510(k) Clearance for Non-Prescription Version of BlueStar® Digital Therapeutic
Digital health leader WellDoc has received FDA 510(k) class II clearance for a non-prescription version of the BlueStar® digital therapeutic diabetes management platform. This news comes on the heels of two other significant recent announcements for BlueStar®: the FDA’s clearance of the wireless integration of LifeScan’s OneTouch Verio Flex® blood glucose monitoring system with BlueStar®, and plans to incorporate the American Association of Diabetes Educators’ (AADE) curriculum in the BlueStar®
Read More
